Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05090566 · ClinicalTrials.gov registry record · Phase 2

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

A Phase 2 study of Multiple Myeloma, sponsored by Pfizer.

Active
Registry status
Phase 2
Development phase
46
Enrollment target
20
Study locations

NCT05090566 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 46 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05090566, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Pfizer.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
46 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Elranatamab + Nirogacestat
  • DRUG Elranatamab + lenalidomide + dexamethasone

Study Locations (20)

California

  • Beverly Hills Cancer Center - Beverly Hills
  • Clinical Research Advisors - Encino
  • Clinical Research Advisors - Los Angeles
  • Cedars Sinai Medical Center Oncology IDS Pharmacy Attn:Suwicha Limvorasak ,PharmaD - Los Angeles
  • Cedars Sinai Medical Center - Los Angeles
  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute (SOCCI) - Los Angeles
  • Clinical Research Advisors - Los Angeles
  • Cedars-Sinai Tarzana - Tarzana

Florida

  • Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center - Coral Gables
  • University of Miami - Coral Gables
  • Sylvester Comprehensive Cancer Center- Deerfield Beach - Deerfield Beach
  • Sylvester Comprehensive Cancer Center - Miami
  • UHealth Tower - Miami

Arizona

  • Banner Gateway Medical Center - Gilbert
  • Banner Gateway Medical Pavilion - Gilbert
  • Banner MD Anderson Cancer Center - Gilbert
  • Banner Health d.b.a. Banner MD Anderson Cancer Center - Phoenix

Maryland

  • The Johns Hopkins University School of Medicine - Baltimore
  • OIDS, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Also Imaging Facility) - Baltimore

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2021-10-27
Est. Completion 2026-03-10
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05090566

The ClinicalTrials.gov registry entry for NCT05090566 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (92% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Elranatamab + Nirogacestat is the first listed.

NCT05090566 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT05090566 about?

NCT05090566 is a clinical study titled "MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma". The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.

What is the current status of trial NCT05090566?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2021-10-27. Estimated completion is 2026-03-10.

What conditions does trial NCT05090566 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT05090566?

The interventions under investigation include: Elranatamab + Nirogacestat (DRUG), Elranatamab + lenalidomide + dexamethasone (DRUG).

Who is sponsoring clinical trial NCT05090566?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05090566 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.